Projet InterTAU (Horizon 2020, appel à projets 2019)
Action : Staff Exchanges
Panel : Life Sciences
Statut du projet : SIGNED

There is an enormous and unmet medical need to find efficient methods of prevention, diagnosis and disease- modifying therapies for neurodegenerative disorders, including Alzheimer’s disease (AD), other tauopathies and Parkinson’s disease (PD). The common molecular denominator of tauopathies are pathological forms of tau protein, and in Parkinson’s disease these are pathological forms of -synuclein. Moreover, -synuclein has a distinct role in pathophysiology of tauopathies, mainly in tau hyperphosphorylation and aggregation, and vice versa. Tau pathology relates to conformational changes during oligomerization and assembly resulting in toxicity. Given their role in the pathogenesis, conformationally altered and assembled tau or -synuclein would be a promising molecular target for disease-modifying therapies. However, the field is still lacking a deeper understanding of associated structural changes in the course of assembly and their inducers on the pathway towards pathological forms of these proteins; therefore, the pharma development is hampered. The main aim of the InterTau project is the detailed structural and biophysical characterization of tau and -synuclein -synuclein protein and their variants in monomeric, oligomeric and fibrillar states relevant for AD, other tauopathies. The InterTAU consortium is composed and academic partners with cutting- edge methodologies suitable for functional and structural characterization of the tau assembly pathway by solution and solid-state nuclear magnetic resonance (NMR), cryo-electron microscopy and cellular assays corroborated by bioinformatics. The mutual transfer of complementary expertise envisaged in the project will facilitate academic outcome and biotechnological development. Specific expertise will be transferred from three institutions in North America and one institution from Argentina. The results of InterTAU will be directly translated into innovation in biotech through the non-academic partner. The platform for sharing knowledge will be a foundation of sustainable cooperation beyond the InterTau project.

Mots clés : solid state nmr, solution nmr, cryo em, protein protein interactions, immunology, tauopathies

Participants :
- Royal College of Surgeons in Ireland (Irlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 92000.0 €
- Masaryk University (Rép. Tchèque) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 384100.0 €
- BioVendor (Czechia) (Rép. Tchèque) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- National University of Cuyo (Argentine) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Geneton (Slovakia) (Slovaquie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Pittsburgh (Etats-Unis) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Neuroimunologicky ustav slovenskejakademia vied (Slovaquie) — Partner, beneficiary, Recherche, subvention : 427800.0 €
- Datamedrix gmbh (Autriche) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 13800.0 €
- AXON Neuroscience (Slovakia) (Slovaquie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 11500.0 €
- Latvian Academy of Sciences (Lettonie) — Partner, beneficiary, Recherche, subvention : 128800.0 €
- Oregon State University (Etats-Unis) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Sanata Dharma University (Indonésie) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- University Health Network (Canada) — Partner, organization partner, Recherche, subvention : 0.0 €